Royalty Pharma plc Class A Ordinary Shares (RPRX)

Price$55.87

Value ScoreD

Growth ScoreC

Momentum ScoreB

Favorite Metrics

Price vs S&P 500 (26W)31.68%

Price vs S&P 500 (4W)10.01%

VGM Score51.84

Market Capitalization$32.17B

P/E Ratio (Annual)41.73x

Indicated Dividend Yield (Annual)1.71%

All Metrics

P/CF (Annual)12.92x

Book Value / Share (Quarterly)$11.96

P/TBV (Annual)4.26x

Indicated Dividend (Annual)$0.94

Revenue Growth (3Y)2.06%

Cash Flow / Share (Quarterly)$0.80

Payout Ratio (TTM)46.83%

Price vs S&P 500 (YTD)36.43%

Net Profit Margin (TTM)33.90%

EPS (TTM)$1.48

10-Day Avg Trading Volume5.30M

EPS Excl Extra (TTM)$1.48

Revenue Growth (5Y)2.30%

EPS (Annual)$1.37

Dividend / Share (Annual)$0.65

ROI (Annual)5.00%

Net Profit Margin (5Y Avg)29.51%

Cash / Share (Quarterly)$2.41

P/E Basic Excl Extra (TTM)38.89x

Revenue Growth QoQ (YoY)10.97%

EPS Growth (5Y)-12.06%

P/E Normalized (Annual)41.73x

ROA (Last FY)3.93%

Revenue Growth TTM (YoY)7.80%

EBITD / Share (TTM)$2.84

ROE (5Y Avg)10.63%

Operating Margin (TTM)65.08%

Cash Flow / Share (Annual)$1.37

P/B Ratio4.67x

P/B Ratio (Quarterly)4.02x

Net Income / Employee (Annual)$7,709,500

EV / Revenue (TTM)16.61x

Net Interest Coverage (TTM)6.99x

ROA (TTM)4.29%

EPS Growth QoQ (YoY)28.35%

EV / EBITDA (TTM)25.53x

EPS Incl Extra (Annual)$1.37

Current Ratio (Annual)2.40x

Quick Ratio (Quarterly)2.66x

3-Month Avg Trading Volume3.67M

52-Week Price Return65.54%

EV / Free Cash Flow (Annual)51.19x

P/E Incl Extra (TTM)38.89x

Revenue / Employee (TTM)$24,405,200

Tangible BV / Share (Quarterly)$12.70

P/S Ratio (Annual)13.53x

Asset Turnover (Annual)0.12x

52-Week High$56.07

Operating Margin (5Y Avg)52.45%

EPS Excl Extra (Annual)$1.37

CapEx CAGR (5Y)-4.90%

26-Week Price Return39.61%

Quick Ratio (Annual)2.40x

13-Week Price Return22.31%

Total Debt / Equity (Annual)1.38x

Current Ratio (Quarterly)2.66x

Enterprise Value$40.54B

Revenue / Share Growth (5Y)-5.71%

Asset Turnover (TTM)0.13x

Book Value / Share Growth (5Y)-2.00%

Revenue / Employee (Annual)$23,781,900

Pretax Margin (Annual)55.68%

Cash / Share (Annual)$2.59

3-Month Return Std Dev21.78%

Net Income / Employee (TTM)$8,272,900

EBITDA CAGR (5Y)-0.36%

EBITDA Interim CAGR (5Y)19.10%

ROE (Last FY)11.90%

Net Interest Coverage (Annual)4.90x

EPS Basic Excl Extra (Annual)$1.37

P/FCF (TTM)44.55x

Receivables Turnover (TTM)150.73x

EV / Free Cash Flow (TTM)87.58x

Total Debt / Equity (Quarterly)1.30x

EPS Incl Extra (TTM)$1.48

Receivables Turnover (Annual)150.73x

ROI (TTM)5.43%

P/S Ratio (TTM)13.18x

Pretax Margin (5Y Avg)50.23%

Revenue / Share (Annual)$4.21

Tangible BV / Share (Annual)$12.70

Forward P/E10.39x

Price vs S&P 500 (52W)41.18%

P/E Ratio (TTM)38.89x

EPS Growth TTM (YoY)-20.07%

Year-to-Date Return44.59%

5-Day Price Return1.25%

EPS Normalized (Annual)$1.37

ROA (5Y Avg)3.87%

Net Profit Margin (Annual)32.42%

Month-to-Date Return0.20%

Cash Flow / Share (TTM)$0.66

EBITD / Share (Annual)$2.76

EPS Growth (3Y)140.90%

Operating Margin (Annual)65.58%

LT Debt / Equity (Annual)1.32x

P/CF (TTM)12.32x

ROI (5Y Avg)5.00%

P/E Excl Extra (TTM)38.89x

LT Debt / Equity (Quarterly)1.25x

EPS Basic Excl Extra (TTM)$1.48

P/TBV (Quarterly)4.26x

Payout Ratio (Annual)49.06%

P/B Ratio (Annual)3.44x

Dividend / Share (TTM)$0.68

Pretax Margin (TTM)55.69%

Book Value / Share (Annual)$11.22

Price vs S&P 500 (13W)14.05%

Net Margin Growth (5Y)-6.73%

Dividend Yield (TTM)1.20%

Beta0.43x

P/FCF (Annual)40.62x

Revenue / Share (TTM)$4.38

ROE (TTM)12.67%

52-Week Low$33.37

vGradeD

gGradeC

mGradeB

vgmGradeC

Show chart for

Earnings Surprise History

Q1 261.30est. 1.24

Analyst Recommendations

Feb 2026

Mar 2026

Apr 2026

May 2026

4.29

4.19

Industry Peers — Pharmaceuticals(550)

Symbol	Value Score	Growth Score	Momentum Score	Price
RPRXRoyalty Pharma plc Class A Ordinary Shares	D	C	B	$55.87
LLYEli Lilly & Co.	D	B	B	$1131.42
JNJJohnson & Johnson	D	C	B	$232.77
ABBVABBVIE INC.	D	C	C	$227.23
MRKMerck & Co., Inc.	C	C	B	$120.79
NVSNovartis AG	C	C	C	$149.16
AZNAstraZeneca PLC	D	B	C	$185.95
NVONovo-Nordisk A/S	B	B	B	$42.96
ABTAbbott Laboratories	C	C	D	$91.07
PFEPfizer Inc.	B	C	C	$26.04
BMYBristol-Myers Squibb Co.	B	C	B	$57.27

About

Royalty Pharma PLC is the largest buyer of biopharmaceutical royalties, generating recurring revenue from fixed payments tied to the sales of commercial medications. The company receives royalties from a diversified portfolio of 35+ approved products across oncology, neurology, and rare genetic diseases, plus 10 development-stage candidates from major pharmaceutical companies including AbbVie, Johnson & Johnson, Biogen, and Vertex. This business model provides predictable cash flows from established market-leading drugs without the operational risks of drug development or commercialization.